About
CNS treatments
Areas of Focus
Categories
Small Molecule PharmaceuticalBoston & New England
Team (5)
David Kupfer, M.D.
Chair of the Nominating and Governance CommitteeMember of the Compensation CommitteeMember of the Audit Committee
Minerva Neurosciences
board_chair
Fouzia Laghrissi-Thode, M.D.
Chair of the Compensation Committee
Minerva Neurosciences
board_chair
Hans Peter Hasler
Member of the Compensation CommitteeMember of the Nominating and Governance CommitteeMember of the Audit Committee
Minerva Neurosciences
team_member
Jan van Heek
Chair of the Audit Committee
Minerva Neurosciences
board_chair
Remy Luthringer, Ph.D.
Minerva Neurosciences
team_member
Clinical Trials (7)
View allTotal Trials
7
As Lead Sponsor
6
As Collaborator
1
Total Enrollment
998
By Phase
PHASE1: 5PHASE2: 1PHASE3: 1
By Status
COMPLETED: 7
Clinical Trials Pipeline7 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Today
Hover over trial bars to see details
Recent Trials
NCT06107803Lead Sponsor
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of Schizophrenia
PHASE1Completed
17 participants
Started: Oct 13, 2023 · Completed: Jan 12, 2024
NCT03446846Lead Sponsor
A Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Patients With Major Depressive Disorder
PHASE2Completed
360 participants
Started: Mar 30, 2018 · Completed: Dec 13, 2019
NCT03397134Lead Sponsor
Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia
PHASE3Completed
515 participants
Started: Dec 15, 2017 · Completed: Feb 15, 2021
NCT03072056Lead Sponsor
A Pharmacokinetic Study of MIN-101 and Its Metabolites in Healthy Subjects to Compare MIN-101 in Poor and Extensive Metabolizers
PHASE1Completed
23 participants
Started: Jan 9, 2017 · Completed: Jul 7, 2017
NCT03038646Lead Sponsor
A Pharmacokinetic Study of Modified Release (MR) Formulations of MIN-101 in Healthy Subjects
PHASE1Completed
14 participants
Started: Nov 30, 2016 · Completed: Apr 20, 2017
Locations (1)
Headquarters
Burlington, MA, United States
Map
Loading map...